Monte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation.
Latest Monte Rosa Therapeutics news
We have not published a story on Monte Rosa Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $90.1 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Monte Rosa Therapeutics
What is the ticker symbol of Monte Rosa Therapeutics?
Monte Rosa Therapeutics, Inc. trades under the ticker GLUE on NASDAQ.
Where is Monte Rosa Therapeutics listed?
Monte Rosa Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Monte Rosa Therapeutics?
The SEC Central Index Key (CIK) for Monte Rosa Therapeutics, Inc. is 1826457. Its filings are on SEC EDGAR.
How many shares does Monte Rosa Therapeutics have outstanding?
85,313,401 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Monte Rosa Therapeutics listed under?
Our directory records Monte Rosa Therapeutics, Inc. under United States.
What does Monte Rosa Therapeutics do?
Our directory classifies Monte Rosa Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Monte Rosa Therapeutics?
The ISIN recorded for Monte Rosa Therapeutics, Inc. is US61225M1027.
Does aibio.space cover Monte Rosa Therapeutics?
aibio.space lists Monte Rosa Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Monte Rosa Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Monte Rosa Therapeutics profitable?
Monte Rosa Therapeutics, Inc. reported a net loss of $38.6 million for the fiscal year ended Dec 31, 2025, and used $22.8 million of cash in operations, per its annual report to the SEC.
How much does Monte Rosa Therapeutics spend on research and development?
$141.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Monte Rosa Therapeutics have?
$90.1 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Monte Rosa Therapeutics (GLUE) stock news?
Our latest story on Monte Rosa Therapeutics, dated Jan 8, 2026: "Monte Rosa upsizes stock sale to $300 million after oral NEK7 degrader cuts CRP 85%". Monte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation. Source.
What is Monte Rosa Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Jan 8, 2026: "Monte Rosa upsizes stock sale to $300 million after oral NEK7 degrader cuts CRP 85%". Monte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation. Source.
Who were the underwriters or placement agents on Monte Rosa Therapeutics's offering?
From our story: Jefferies, TD Cowen and Piper Sandler were joint book-runners, and Wedbush PacGrow and LifeSci Capital were passive book-runners. Source.
Investor discussion: Monte Rosa Therapeutics
Members talk about Monte Rosa Therapeutics (GLUE). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Monte Rosa Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:GLUE on TradingView.
SEC filings and registration
SEC name
Monte Rosa Therapeutics, Inc.
CIK
1826457
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
GLUE (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
321 HARRISON AVENUE, BOSTON, MA, 02118
Phone
617-949-2643
Shares outstanding
85,313,401 as of 2026-07-31 (10-Q filed 2026-08-06)
Former names
Monte Rosa Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Monte Rosa Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GLUE, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio